Form 4: Apogee CEO Henderson Granted Stock Options

Apogee Therapeutics CEO Michael Henderson was granted 253,016 stock options with a $75.78 exercise price, vesting over four years.

Summary

• Michael Thomas Henderson, Chief Executive Officer and Director of Apogee Therapeutics, Inc. (APGE), was granted stock options.
• The grant, dated January 2, 2026, is for the right to purchase 253,016 shares of the Issuer's common stock.
• The exercise price for these options is $75.78 per share.
• The options will vest in forty-eight equal monthly installments over a four-year period from the grant date, contingent on Mr. Henderson's continued service to the Issuer.
• The expiration date for these stock options is January 2, 2036.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The grant of stock options to the CEO is a positive event for executive alignment and retention, as it ties the executive's financial success directly to the company's stock performance over the long term. It is a routine compensation event and does not directly reflect company operational performance, hence a moderately positive score.

Positives

• The grant of stock options aligns the Chief Executive Officer's long-term financial interests with those of the shareholders, incentivizing sustained performance and value creation.
• The vesting schedule over four years encourages executive retention and commitment to the company's strategic objectives.

Future Outlook

The vesting schedule of the stock options over a four-year period indicates an expectation of continued service from the Chief Executive Officer, aligning his incentives with the company's long-term performance and strategic goals.

Industry Context

The grant of stock options to a Chief Executive Officer is a standard practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages designed to attract, retain, and motivate top talent. This practice aligns executive incentives with shareholder value creation over the long term, a common strategy among publicly traded companies, particularly those in growth-oriented sectors like therapeutics.

Comparison to Industry Standards

• The use of stock options with a multi-year vesting schedule is a common executive compensation tool across the biotechnology sector, comparable to practices at companies like Moderna, BioNTech, or Regeneron, which frequently utilize equity awards to incentivize leadership.
• The specific exercise price of $75.78 reflects the market price at the time of grant, a standard approach for 'at-the-money' options, similar to grants observed at peer companies during their respective grant dates.
• The four-year vesting period is typical for executive equity grants, providing a long-term incentive structure that is consistent with industry benchmarks for executive retention and performance alignment.

Stakeholder Impact

• Shareholders: The grant aligns the CEO's interests with shareholders, potentially leading to increased focus on long-term stock appreciation.
• Employees: May signal stability in leadership and a commitment to long-term growth, potentially boosting morale.

Next Steps

• Michael Henderson's continued service to Apogee Therapeutics, Inc. is required for the vesting of the stock options over the next four years.

Key Dates

Keywords

Apogee Therapeutics, APGE, stock option, executive compensation, Form 4, Michael Henderson, insider transaction, equity compensation, Rule 10b5-1